Skip to main content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 1/2018

19-04-2017 | Special Section: Measuring What Matters (by invitation only)

Beyond study participants: a framework for engaging patients in the selection or development of clinical outcome assessments for evaluating the benefits of treatment in medical product development

Auteurs: Hilary Wilson, Ebony Dashiell-Aje, Milena Anatchkova, Karin Coyne, Asha Hareendran, Nancy Kline Leidy, Colleen A. McHorney, Kathy Wyrwich

Gepubliceerd in: Quality of Life Research | Uitgave 1/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Background

Patients are participating more actively in health care decision-making with regard to their health, as well as in the broader realm of assessing the value of medical products and influencing decisions about their registration and reimbursement. There is an increasing trend to include patients’ perspectives throughout the stages of medical product development by broadening the traditional study-participant role to that of an active partner throughout the process. Including patients in the selection and development of clinical outcome assessments (COAs) to evaluate the benefit of treatment is particularly important. Still, despite widespread enthusiasm, there is substantial uncertainty regarding how and when to engage patients in this process.

Purpose

This manuscript proposes a methodological framework for engaging patients at varying levels in the selection and development of COAs for medical product development.

Framework

The framework builds on the Food and Drug Administration’s roadmap for patient-focused COA. Methods for engaging patients across each stage in this roadmap are summarized by levels of engagement. Opportunities and examples of patient engagement (PE) in the selection and/or development of COAs are summarized, together with best practices and practical considerations.

Conclusion

This paper offers a framework for understanding, planning, and implementing methods to advance PE in the selection and/or development of COAs for evaluating the benefit of medical products. The intent is to further this important discussion and enhance the process and outcome of PE in this context.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
3.
go back to reference Food Drug Administration (FDA). (2009). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133. Food Drug Administration (FDA). (2009). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133.
4.
go back to reference Carman, K. L., Dardess, P., Maurer, M., Sofaer, S., Adams, K., Bechtel, C., et al. (2013). Patient and family engagement: a framework for understanding the elements and developing interventions and policies. Health Affairs (Millwood), 32(2), 223–231. doi: 10.​1377/​hlthaff.​2012.​1133. CrossRef Carman, K. L., Dardess, P., Maurer, M., Sofaer, S., Adams, K., Bechtel, C., et al. (2013). Patient and family engagement: a framework for understanding the elements and developing interventions and policies. Health Affairs (Millwood), 32(2), 223–231. doi: 10.​1377/​hlthaff.​2012.​1133. CrossRef
5.
go back to reference Boutin, M., Dewulf, L., Hoos, A., & et al. (2016). Culture and Process Change as a Priority for Patient Engagement in Medicines Development. Therapeutic Innovation & Regulatory Science. Boutin, M., Dewulf, L., Hoos, A., & et al. (2016). Culture and Process Change as a Priority for Patient Engagement in Medicines Development. Therapeutic Innovation & Regulatory Science.
6.
go back to reference Patient Focused Medicines Development (2016). patientfocusedmedicines.org. Available at: patientfocusedmedicnes.org. Accessed November 21 2016. Patient Focused Medicines Development (2016). patientfocusedmedicines.org. Available at: patientfocusedmedicnes.org. Accessed November 21 2016.
7.
go back to reference Hanna, M. L., Oehrlein, E. M., Perfetto, E. M., Astratinei, V., Berner, T., Burke, L. B., et al. (2016). Attributes Definiting Patient Engagement and Centeredness in Health Care Research and Practice: A Framework Developed by the ISPOR Patient- Centered Special Interest Group. Paper presented at the ISPOR 19th Annual European Congress, Vienna, Austria, October 29-November 2, 2016. Hanna, M. L., Oehrlein, E. M., Perfetto, E. M., Astratinei, V., Berner, T., Burke, L. B., et al. (2016). Attributes Definiting Patient Engagement and Centeredness in Health Care Research and Practice: A Framework Developed by the ISPOR Patient- Centered Special Interest Group. Paper presented at the ISPOR 19th Annual European Congress, Vienna, Austria, October 29-November 2, 2016.
8.
go back to reference National Health Council/Genetic Alliance (2015). Dialogue/advancing meaningful patient engagement in research, development, and review of drugs. National Health Council/Genetic Alliance (2015). Dialogue/advancing meaningful patient engagement in research, development, and review of drugs.
13.
go back to reference eyeforpharma Patient-Centric Profitability: Pharma’s global survey & analysis. A discussion of results from The Aurora Project:19. eyeforpharma Patient-Centric Profitability: Pharma’s global survey & analysis. A discussion of results from The Aurora Project:19.
25.
27.
30.
go back to reference Cook, K. F., Kallen, M. A., Victorson, D., & Miller, D. (2015). How much change really matters? Development and comparison of two novel approaches to defining clinically important differences in fatigue scores. Quality of Life Research, 24(Suppl 1), 157–158. Cook, K. F., Kallen, M. A., Victorson, D., & Miller, D. (2015). How much change really matters? Development and comparison of two novel approaches to defining clinically important differences in fatigue scores. Quality of Life Research, 24(Suppl 1), 157–158.
31.
go back to reference Gelhorn, H. L., Kulke, M. H., O’Dorisio, T., Yang, Q. M., Jackson, J., Jackson, S., et al. (2016). Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: A qualitative interview approach. Clinical Therapeutics, 38(4), 759–768. doi: 10.​1016/​j.​clinthera.​2016.​03.​002. CrossRefPubMed Gelhorn, H. L., Kulke, M. H., O’Dorisio, T., Yang, Q. M., Jackson, J., Jackson, S., et al. (2016). Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: A qualitative interview approach. Clinical Therapeutics, 38(4), 759–768. doi: 10.​1016/​j.​clinthera.​2016.​03.​002. CrossRefPubMed
33.
go back to reference Thissen, D., Liu, Y., Magnus, B., Quinn, H., Gipson, D. S., Dampier, C., et al. (2016). Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. Quality of Life Research, 25(1), 13–23. doi: 10.​1007/​s11136-015-1058-8. CrossRefPubMed Thissen, D., Liu, Y., Magnus, B., Quinn, H., Gipson, D. S., Dampier, C., et al. (2016). Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. Quality of Life Research, 25(1), 13–23. doi: 10.​1007/​s11136-015-1058-8. CrossRefPubMed
39.
go back to reference Mannix, S., Skalicky, A., Buse, D. C., Desai, P., Sapra, S., Ortmeier, B., et al. (2016). Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. Health and Quality Life Outcomes, 14(1), 143. doi: 10.​1186/​s12955-016-0542-3. CrossRef Mannix, S., Skalicky, A., Buse, D. C., Desai, P., Sapra, S., Ortmeier, B., et al. (2016). Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. Health and Quality Life Outcomes, 14(1), 143. doi: 10.​1186/​s12955-016-0542-3. CrossRef
40.
go back to reference Hareendran, A., Setyawan, J., Pokrzywinski, R., Steenrod, A., Madhoo, M., & Erder, M. H. (2015). Evaluating functional outcomes in adolescents with attention-deficit/hyperactivity disorder: development and initial testing of a self-report instrument. Health and Quality Life Outcomes, 13, 133. doi: 10.​1186/​s12955-015-0302-9. CrossRef Hareendran, A., Setyawan, J., Pokrzywinski, R., Steenrod, A., Madhoo, M., & Erder, M. H. (2015). Evaluating functional outcomes in adolescents with attention-deficit/hyperactivity disorder: development and initial testing of a self-report instrument. Health and Quality Life Outcomes, 13, 133. doi: 10.​1186/​s12955-015-0302-9. CrossRef
45.
go back to reference Merkel, P. A., Manion, M., Gopal-Srivastava, R., Groft, S., Jinnah, H. A., Robertson, D., et al. (2016). The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet Journal of Rare Diseases, 11(1), 66. doi: 10.​1186/​s13023-016-0445-8. CrossRefPubMedPubMedCentral Merkel, P. A., Manion, M., Gopal-Srivastava, R., Groft, S., Jinnah, H. A., Robertson, D., et al. (2016). The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet Journal of Rare Diseases, 11(1), 66. doi: 10.​1186/​s13023-016-0445-8. CrossRefPubMedPubMedCentral
55.
go back to reference Agency for Healthcare Research and Quality (2014). Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)- EHC063- EF. Rockville, MD. Agency for Healthcare Research and Quality (2014). Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)- EHC063- EF. Rockville, MD.
60.
go back to reference Food and Drug Administration. (2012). Prescription Drug User Fee Act V patient-focused drug development; public meeting and request for comment. Federal Register, 77, 58848–58849. Food and Drug Administration. (2012). Prescription Drug User Fee Act V patient-focused drug development; public meeting and request for comment. Federal Register, 77, 58848–58849.
Metagegevens
Titel
Beyond study participants: a framework for engaging patients in the selection or development of clinical outcome assessments for evaluating the benefits of treatment in medical product development
Auteurs
Hilary Wilson
Ebony Dashiell-Aje
Milena Anatchkova
Karin Coyne
Asha Hareendran
Nancy Kline Leidy
Colleen A. McHorney
Kathy Wyrwich
Publicatiedatum
19-04-2017
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 1/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1577-6

Andere artikelen Uitgave 1/2018

Quality of Life Research 1/2018 Naar de uitgave

Special Section: Measuring What Matters (by invitation only)

Prioritizing research topics: a comparison of crowdsourcing and patient registry